Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.

Lindström S, Ma J, Altshuler D, Giovannucci E, Riboli E, Albanes D, Allen NE, Berndt SI, Boeing H, Bueno-de-Mesquita HB, Chanock SJ, Dunning AM, Feigelson HS, Gaziano JM, Haiman CA, Hayes RB, Henderson BE, Hunter DJ, Kaaks R, Kolonel LN, Le Marchand L, Martínez C, Overvad K, Siddiq A, Stampfer M, Stattin P, Stram DO, Thun MJ, Trichopoulos D, Tumino R, Virtamo J, Weinstein SJ, Yeager M, Kraft P, Freedman ML.

J Clin Endocrinol Metab. 2010 Sep;95(9):E121-7. doi: 10.1210/jc.2009-1911. Epub 2010 Jun 9.

2.

Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era.

Platz EA, Leitzmann MF, Rifai N, Kantoff PW, Chen YC, Stampfer MJ, Willett WC, Giovannucci E.

Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1262-9.

3.

CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium.

Travis RC, Schumacher F, Hirschhorn JN, Kraft P, Allen NE, Albanes D, Berglund G, Berndt SI, Boeing H, Bueno-de-Mesquita HB, Calle EE, Chanock S, Dunning AM, Hayes R, Feigelson HS, Gaziano JM, Giovannucci E, Haiman CA, Henderson BE, Kaaks R, Kolonel LN, Ma J, Rodriguez L, Riboli E, Stampfer M, Stram DO, Thun MJ, Tjønneland A, Trichopoulos D, Vineis P, Virtamo J, Le Marchand L, Hunter DJ.

Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2734-44. doi: 10.1158/1055-9965.EPI-09-0496. Epub 2009 Sep 29.

4.

Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor.

Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW, Coetzee GA.

J Natl Cancer Inst. 1997 Jan 15;89(2):166-70.

5.

Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.

Canzian F, Cox DG, Setiawan VW, Stram DO, Ziegler RG, Dossus L, Beckmann L, Blanché H, Barricarte A, Berg CD, Bingham S, Buring J, Buys SS, Calle EE, Chanock SJ, Clavel-Chapelon F, DeLancey JO, Diver WR, Dorronsoro M, Haiman CA, Hallmans G, Hankinson SE, Hunter DJ, Hüsing A, Isaacs C, Khaw KT, Kolonel LN, Kraft P, Le Marchand L, Lund E, Overvad K, Panico S, Peeters PH, Pollak M, Thun MJ, Tjønneland A, Trichopoulos D, Tumino R, Yeager M, Hoover RN, Riboli E, Thomas G, Henderson BE, Kaaks R, Feigelson HS.

Hum Mol Genet. 2010 Oct 1;19(19):3873-84. doi: 10.1093/hmg/ddq291. Epub 2010 Jul 15.

6.

Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer.

Hakimi JM, Schoenberg MP, Rondinelli RH, Piantadosi S, Barrack ER.

Clin Cancer Res. 1997 Sep;3(9):1599-608.

7.

Polymorphic CAG/CAA repeat length in the AIB1/SRC-3 gene and prostate cancer risk: a population-based case-control study.

Hsing AW, Chokkalingam AP, Gao YT, Wu G, Wang X, Deng J, Cheng J, Sesterhenn IA, Mostofi FK, Chiang T, Chen YL, Stanczyk FZ, Chang C.

Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):337-41.

8.

A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3).

Cox DG, Blanché H, Pearce CL, Calle EE, Colditz GA, Pike MC, Albanes D, Allen NE, Amiano P, Berglund G, Boeing H, Buring J, Burtt N, Canzian F, Chanock S, Clavel-Chapelon F, Feigelson HS, Freedman M, Haiman CA, Hankinson SE, Henderson BE, Hoover R, Hunter DJ, Kaaks R, Kolonel L, Kraft P, LeMarchand L, Lund E, Palli D, Peeters PH, Riboli E, Stram DO, Thun M, Tjonneland A, Trichopoulos D, Yeager M; Breast and Prostate Cancer Cohort Consortium.

Breast Cancer Res. 2006;8(5):R54.

9.
10.

Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat.

Rebbeck TR, Kantoff PW, Krithivas K, Neuhausen S, Blackwood MA, Godwin AK, Daly MB, Narod SA, Garber JE, Lynch HT, Weber BL, Brown M.

Am J Hum Genet. 1999 May;64(5):1371-7.

11.

Polymorphic CAG and GGC repeat lengths in the androgen receptor gene and prostate cancer risk: analysis of a Brazilian population.

Silva Neto B, Koff WJ, Biolchi V, Brenner C, Biolo KD, Spritzer PM, Brum IS.

Cancer Invest. 2008 Feb;26(1):74-80. doi: 10.1080/07357900701638251.

PMID:
18181049
12.

The polymorphic exon 1 androgen receptor CAG repeat in men with a potential inherited predisposition to prostate cancer.

Lange EM, Chen H, Brierley K, Livermore H, Wojno KJ, Langefeld CD, Lange K, Cooney KA.

Cancer Epidemiol Biomarkers Prev. 2000 Apr;9(4):439-42.

13.

The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses' Health Study.

Haiman CA, Brown M, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Kantoff PW, Hunter DJ.

Cancer Res. 2002 Feb 15;62(4):1045-9.

14.
15.

Interactions between genome-wide significant genetic variants and circulating concentrations of insulin-like growth factor 1, sex hormones, and binding proteins in relation to prostate cancer risk in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.

Tsilidis KK, Travis RC, Appleby PN, Allen NE, Lindstrom S, Schumacher FR, Cox D, Hsing AW, Ma J, Severi G, Albanes D, Virtamo J, Boeing H, Bueno-de-Mesquita HB, Johansson M, Quirós JR, Riboli E, Siddiq A, Tjønneland A, Trichopoulos D, Tumino R, Gaziano JM, Giovannucci E, Hunter DJ, Kraft P, Stampfer MJ, Giles GG, Andriole GL, Berndt SI, Chanock SJ, Hayes RB, Key TJ.

Am J Epidemiol. 2012 May 1;175(9):926-35. doi: 10.1093/aje/kwr423. Epub 2012 Mar 29.

16.

The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness.

Sun T, Oh WK, Jacobus S, Regan M, Pomerantz M, Freedman ML, Lee GS, Kantoff PW.

Cancer Prev Res (Phila). 2011 Dec;4(12):2044-50. doi: 10.1158/1940-6207.CAPR-11-0283. Epub 2011 Sep 7.

17.

Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.

Chen YC, Kraft P, Bretsky P, Ketkar S, Hunter DJ, Albanes D, Altshuler D, Andriole G, Berg CD, Boeing H, Burtt N, Bueno-de-Mesquita B, Cann H, Canzian F, Chanock S, Dunning A, Feigelson HS, Freedman M, Gaziano JM, Giovannucci E, Sánchez MJ, Haiman CA, Hallmans G, Hayes RB, Henderson BE, Hirschhorn J, Kaaks R, Key TJ, Kolonel LN, LeMarchand L, Ma J, Overvad K, Palli D, Pharaoh P, Pike M, Riboli E, Rodriguez C, Setiawan VW, Stampfer M, Stram DO, Thomas G, Thun MJ, Travis RC, Virtamo J, Trichopoulou A, Wacholder S, Weinstein SJ.

Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):1973-81.

18.

Androgen receptor CAG repeats and prostate cancer.

Nelson KA, Witte JS.

Am J Epidemiol. 2002 May 15;155(10):883-90. Review.

19.

Polymorphic GGC repeats in the androgen receptor gene are associated with hereditary and sporadic prostate cancer risk.

Chang BL, Zheng SL, Hawkins GA, Isaacs SD, Wiley KE, Turner A, Carpten JD, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB, Xu J.

Hum Genet. 2002 Feb;110(2):122-9. Epub 2002 Jan 23.

PMID:
11935317
20.
Items per page

Supplemental Content

Write to the Help Desk